Clinically reviewed by Melissa Lemeteyer, NP
If you’ve had an eating disorder or struggled with disordered eating in the past, you might be wondering whether that means GLP-1 medications are completely off the table.
The short answer: not necessarily. But it does mean this decision deserves extra care.
GLP-1 medications affect hunger, fullness, food intake, and the reward systems involved in eating. Those effects are part of how these medications work—but they also overlap directly with some of the behaviors and thought patterns involved in eating disorders.
And despite the enormous growth in GLP-1 use, we still have surprisingly little research on how these medications affect people with current or past eating disorders. A 2026 scoping review found that the available research was limited largely to small studies and people with binge eating disorder, with very little evidence about other eating disorders or the potential for GLP-1s to trigger or worsen eating disorder symptoms.
So having a history of disordered eating does not automatically give you a yes or no answer. It means your clinician needs enough information—and you may need more support—to figure out what is safest for you.
This is especially important for LGBTQ+ people
Eating disorders affect people of every gender and sexual orientation, but LGBTQ+ communities experience eating disorders and disordered eating at disproportionately high rates.
A review of U.S. research found that sexual minority adults had roughly two to four times the odds of anorexia nervosa, bulimia nervosa, or binge eating disorder compared with cisgender heterosexual adults. Research also consistently finds elevated eating disorder symptoms among transgender and gender-diverse people.
Among more than 5,000 transgender and gender-diverse college students in one national study, roughly one-third or more screened at elevated risk for an eating disorder, depending on gender identity.
And in The Trevor Project’s survey of LGBTQ+ young people ages 13–24, 9% reported having been diagnosed with an eating disorder, while another 29% said they suspected they had one but had not been diagnosed. Rates were particularly high among transgender boys and men and nonbinary young people assigned female at birth.
Being LGBTQ+ does not inherently cause an eating disorder. Researchers point instead to factors including minority stress, stigma and discrimination, bullying, body-image pressures, and—in some transgender and nonbinary people—the complicated relationship between food, body shape, and gender dysphoria.
That context matters at FOLX. We don’t want to assume an eating disorder looks one particular way, happens in one type of body, or has the same relationship to gender and body image for every person.
What counts as disordered eating?
You do not need to have been formally diagnosed with anorexia, bulimia, binge eating disorder, or another eating disorder for your eating history to be relevant to your care.
At FOLX, we want to know about diagnosed eating disorders and patterns that could suggest disordered eating or an undiagnosed eating disorder.
Those might include things like:
- Frequently restricting food or skipping meals to change your body or weight
- Binge eating or regularly feeling out of control around food
- Purging, including vomiting or using laxatives
- Exercising specifically to compensate for eating
- Having rigid rules about what, when, or how much you are allowed to eat
- Feeling significant guilt or shame after eating
- Becoming intensely preoccupied with calories, food, weight, or body size
- Cycling between significant restriction and periods of overeating
Disordered eating exists on a spectrum, and not everyone experiencing these behaviors meets diagnostic criteria for an eating disorder. But you don’t need a formal diagnosis for those patterns to be important to your clinician.
Why can GLP-1s be complicated if you have an eating disorder history?
GLP-1 medications can make people feel full sooner, reduce hunger, and change food-related reward and motivation. For many people, those are expected effects of the medication.
For someone with a history of restrictive eating, bingeing, purging, compulsive exercise, or intense preoccupation with food and weight, however, those changes may interact with an eating disorder in ways we don’t yet fully understand.
Potential concerns include difficulty eating enough or eating regularly, using appetite suppression to facilitate restriction, or seeing old thoughts and behaviors around food and body image begin to return.
At the same time, this is not a simple story of “GLP-1s are bad for eating disorders.” Early studies have suggested that GLP-1 medications could potentially reduce binge-eating symptoms for some people with binge eating disorder. But the research is small, short-term, and heavily concentrated on BED; we know much less about people with restrictive eating disorders, a previous eating disorder, or subclinical disordered eating.
A joint clinical advisory from several major nutrition and obesity-medicine organizations recommends screening people for eating disorders before GLP-1 treatment and involving eating-disorder expertise when someone screens positive or has an eating disorder history.
And we need to talk about size bias
One reason eating disorder screening has to go beyond a diagnosis in your medical chart: eating disorders are frequently missed in people in larger bodies.
There is still a widespread stereotype that someone with an eating disorder will look visibly thin. In reality, serious restrictive eating disorders can occur at many body sizes.
Research on weight stigma in eating disorder care has found that people at higher weights are less likely to be recognized as having an eating disorder, may wait longer for diagnosis and treatment, and may be perceived by clinicians as needing less intensive treatment than thinner patients with similar symptoms.
Sometimes the bias is even more direct: a person may be praised for significant weight loss or encouraged to restrict their food intake without anyone asking how that weight loss is happening.
That can create a particularly confusing situation around GLP-1 care. You may have spent years hearing from healthcare providers that you should lose weight, only to now be asked whether your attempts to do so ever involved restriction, bingeing, purging, or other disordered behaviors.
Both things can be true: a clinician may want to help you address a health concern and your relationship with food deserves to be evaluated independently of your body size.
Weight stigma can also damage trust. Reviews of primary-care research have found that patients who experience weight bias report poorer communication and trust and are more likely to delay or avoid healthcare altogether.
For LGBTQ+ people—who may already have experiences of being misunderstood, judged, or discriminated against in healthcare—creating a setting where someone can talk candidly about food, weight, gender, and their body is especially important.
You may need more support than telehealth alone can provide
If you currently have an eating disorder, have a significant history of one, or your answers suggest that an eating disorder may be present, FOLX may recommend that you see an in-person provider before starting or continuing a GLP-1.
That isn't necessarily because a GLP-1 can never be an option for you.
It is because eating disorders can require closer medical and nutritional monitoring than a telehealth GLP-1 program is designed to provide. An in-person clinician or eating disorder specialist can more fully evaluate your current eating patterns, physical health, nutrition, mental health, treatment history, and risk of symptoms returning.
For some people, that evaluation may ultimately support using a GLP-1 with additional monitoring. For others, treating an eating disorder or establishing more support first may be the safer option.
Be honest with your clinician—even if you're afraid the answer will be no
We understand why someone might be tempted to leave an eating disorder off their medical history or minimize behaviors because they're worried it will prevent them from getting a medication they want.
But your clinician needs the full story to prescribe safely.
That includes eating disorders that happened years ago, symptoms that never resulted in a diagnosis, and behaviors you aren't sure “count.”
This isn't about proving that you're recovered enough or saying the right thing to qualify for medication. It's clinical information about how a treatment that significantly affects hunger and eating might affect you.
Intentionally providing inaccurate medical information can prevent your clinician from making a safe prescribing decision. It may mean FOLX cannot safely prescribe the medication and, in serious circumstances where we cannot establish the information needed to provide safe treatment, can affect our ability to continue providing care.
If you're scared that being honest will automatically disqualify you, tell your clinician that, too. That fear is part of the conversation.
What if you're already taking a GLP-1 and notice your relationship with food changing?
Pay attention to it, and talk with your healthcare provider.
Changes worth bringing up can include:
- Increasingly skipping meals or going long periods without eating
- Feeling anxious, ashamed, or guilty about eating
- Becoming intensely focused on losing more and more weight
- Returning to bingeing, purging, or compensatory exercise
- Feeling successful or proud specifically because you can eat very little
- Regularly overriding signs that your body needs food
- Finding that weight, calories, food, or your body are taking up much more mental space
- Noticing behaviors or thoughts that feel familiar from a previous eating disorder
You do not have to wait for something to become an emergency—or meet every criterion for an eating disorder—to ask for help.
If you're struggling, we want to help you get connected to care
The goal of asking about disordered eating isn't simply to decide whether you qualify for a GLP-1. It's to identify when you might need additional support and help you find it.
Eating disorder treatment can include medical care, therapy, nutrition support, peer support, or specialized eating disorder treatment depending on your needs.
The National Eating Disorders Association (NEDA) offers a free confidential screening tool and a directory of eating disorder treatment providers.
The National Association of Anorexia Nervosa and Associated Disorders (ANAD) also offers free peer support, including a virtual LGBTQIA+ eating disorder support group that does not require a diagnosis or referral.
So, can you take a GLP-1 if you've had an eating disorder?
Maybe. A history of an eating disorder or disordered eating doesn't automatically answer that question.
But it does mean we need to take the history seriously.
The evidence around GLP-1 medications and eating disorders is still developing. We know enough to know that screening and monitoring matter—but not enough to assume every eating disorder, every body, or every person's relationship with food will respond the same way.
For FOLX members, that may mean recommending an in-person evaluation or eating-disorder specialist before prescribing. It also means taking your eating behaviors seriously regardless of your size, understanding the particular pressures LGBTQ+ people can experience around bodies and healthcare, and giving you space to tell the truth about your history without judgment.
The goal isn't simply getting to “yes” or “no” on a prescription.
It's figuring out what care is actually safe and supportive for you.
Sources
- Nagata JM, et al. Emerging Trends in Eating Disorders among Sexual and Gender Minorities. Current Psychiatry Reports, 2021.
- Rasmussen SM, et al. Eating disorders and disordered eating behaviors in the LGBT population: a review of the literature. Journal of Eating Disorders, 2020.
- The Trevor Project. Eating Disorders among LGBTQ Youth, 2022.
- McEntee ML, et al. Dismantling weight stigma in eating disorder treatment: Next steps for the field. Frontiers in Psychiatry, 2023.
- Aoun L, et al. GLP-1 receptor agonists: A novel pharmacotherapy for binge eating? A systematic review. Journal of Clinical & Translational Endocrinology, 2024.
- A scoping review on weight loss injections and eating disorders: therapeutic impact, risks of misuse, and emerging harms, 2026.
